Amrubicin monotherapy for elderly patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective study

Background Previous studies have shown amrubicin (AMR) to be an effective second‐line treatment option for small‐cell lung cancer (SCLC). However, the efficacy of AMR in elderly patients with relapsed SCLC has not been sufficiently evaluated. Methods The medical records of elderly patients with rela...

Full description

Saved in:
Bibliographic Details
Published in:Thoracic cancer 2018-10, Vol.9 (10), p.1279-1284
Main Authors: Sone, Hideyuki, Igawa, Satoshi, Kasajima, Masashi, Ishihara, Mikiko, Hiyoshi, Yasuhiro, Hosotani, Shinji, Ohe, Shuntaro, Ito, Hiroki, Kaizuka, Nobuki, Manaka, Hiroya, Fukui, Tomoya, Mitsufuji, Hisashi, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Naoki, Katsuhiko
Format: Article
Language:English
Subjects:
Abdomen
Aged patients
Amrubicin
Cancer
Cancer therapies
Chemotherapy
Development and progression
Drug dosages
elderly patient
Lung cancer
Lung cancer, Small cell
Medical prognosis
Medical records
Metastasis
Neutropenia
Neutrophils
NMR
Nuclear magnetic resonance
Older people
Oncology, Experimental
Original
Patients
Response rates
small‐cell lung cancer
Studies
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Previous studies have shown amrubicin (AMR) to be an effective second‐line treatment option for small‐cell lung cancer (SCLC). However, the efficacy of AMR in elderly patients with relapsed SCLC has not been sufficiently evaluated. Methods The medical records of elderly patients with relapsed SCLC who received AMR as second‐line chemotherapy were retrospectively reviewed, and their treatment outcomes were evaluated. Results Thirty‐one patients with a median age of 72 years (22 patients with sensitive relapse and 9 with refractory relapse) were analyzed. The median number of treatment cycles was four (range: 1–10), and the response rate was 29%. The median progression‐free survival (PFS) and overall survival (OS) were 5.4 and 11.6 months, respectively. The OS of 22 patients who received third‐line chemotherapy was 15.5 months. The PFS (6.2 vs. 3.2 months; P = 0.002) and OS (14.8 vs. 5.7 months; P = 0.004) were significantly longer in patients with sensitive relapse than those with refractory relapse. The frequency of grade 3 or higher neutropenia was high (n = 18, 58%), while febrile neutropenia was only observed in five patients (16%). Non‐hematological toxic effects were relatively mild, and pneumonitis and treatment‐related deaths were not observed. Conclusion AMR may be a feasible and effective regimen for elderly patients with relapsed SCLC.
ISSN:1759-7706
1759-7714
DOI:10.1111/1759-7714.12833